Key result
Perioperative cessation of antiplatelet or anticoagulant drugs during TURP increased cardiovascular events (9.2% vs 0%, P≤0.01), while both cessation and continuation increased bleeding morbidity.
Why the study?
Does the perioperative cessation or continuation of antiplatelet or anticoagulant medications affect bleeding and cardiovascular events in patients undergoing transurethral prostatectomy?
Observational (n=163)
Does the perioperative cessation or continuation of antiplatelet or anticoagulant medications affect bleeding and cardiovascular events in patients undergoing transurethral prostatectomy?
Absolute Event Rate: 20% vs 9.9%
p-value: p=< 0.01
Withholding antiplatelet or anticoagulant medications for secondary prevention during transurethral prostatectomy significantly increases the risk of cardiovascular and cerebrovascular complications.
No takes yet. Share an insight, caveat, or question.
Cessation of antithrombotics during TURP was associated with CV events; leaves optimal perioperative strategy open pending randomized trials.
Taylor et al. (2011) conducted an observational in Transurethral prostatectomy (n=163). Antiplatelet or anticoagulant medication (ceased or continued) vs. No antiplatelet or anticoagulant medication was evaluated on Bleeding-associated morbidity (p=< 0.01). Perioperative cessation of antiplatelet or anticoagulant drugs during TURP increased cardiovascular events (9.2% vs 0%, P≤0.01), while both cessation and continuation increased bleeding morbidity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: